Friday, September 29, 2017 10:15 PM ET
Audentes Therapeutics (BOLD) sees Significant Insider Sales Extending the Trend of Last Quarter
A substantial level of insider sales in Audentes Therapeutics was disclosed in form 4 documents filed with the SEC today. Two insiders — OrbiMed Advisors Llc, 10% Owner, and Dr Louis G Lange, Director — disposed of 683,000 shares in the company having a market value of approximately $19,295,903. There have been 2 insiders with buy/sell transactions in the past 90 days prior to these filings. All of these trades have been sales resulting in the disposition of 33,000 company shares. Adding the most recent activity to this 90-day history indicates insider trades have seen net sales of 716,000 shares and have averaged 179,000 shares per transaction over this time period.
Over the last 90 days, the number of insider buy/sell trades at Audentes Therapeutics is greater than the 266-company peer group average. Bio Therapeutic Drugs peer group saw 313 buy/sell trades during this period for an average of 1.2 transactions per company. The number of shares per buy/sell trade for Audentes Therapeutics insiders was also higher. Within the peer group there were 8,808,983 shares purchased and 19,764,511 shares sold with company insiders having sold 35,002 shares on average.
In determining significant insider buying and selling, trades reported to the SEC that involve awards, options, exercise of derivative securities, company buy-backs, taxes, gifts, shares acquired via inheritance and tenders or exchange offers have been eliminated in data used to evaluate and write this story.
Today’s Insider Activity
* OrbiMed Advisors Llc, 10% Owner, sold 672,000 shares
* Dr Louis G Lange, Director, sold 11,000 shares
Using proprietary Natural Language Generation (NLG) technology, UpTick evaluates corporate insider filings reported to the SEC and creates real-time news and analysis to report the most significant insider transactions based on transaction type, size and historical trends.
For more information, contact UpTick at email@example.com. Copyright 2017 UpTick Data Technologies. All rights reserved.